tiprankstipranks
Artivion (DE:CYL)
FRANKFURT:CYL

Artivion (CYL) Stock Price & Analysis

0 Followers

CYL Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€11.70 - €19.94
Previous Close€19.04
Volume0.00
Average Volume (3M)140.00
Market Cap
€798.62M
Enterprise Value€1.08B
Total Cash (Recent Filing)$58.94M
Total Debt (Recent Filing)$358.34M
Price to Earnings (P/E)N/A
Beta1.05
May 02, 2024
-€0.11
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,225,138
10 Day Avg. Volume0
30 Day Avg. Volume140
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-6.09
Price to Sales (P/S)8.42
Price to Cash Flow (P/CF)19.40
P/FCF Ratio4.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit4.72
Enterprise Value/Ebitda40.34
Forecast
Price Target Upside23.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say
Clinical Trial ResultsPositive full data from the PERSEVERE study of AMDS presented at a significant medical conference showed a substantial reduction in mortality and adverse events, bolstering confidence in its potential FDA approval.
Executive AppointmentLance Berry is set to take over as CFO, bringing a positive reputation from his tenure at Wright Medical, which may instill investor confidence in the company's future financial leadership.
GuidanceThe Company provided revenue guidance for the next year that exceeds market expectations, indicating a strong financial outlook.
Bears Say
Executive Team ChangeCFO Ashley Lee, having steered the company through significant growth, is set to retire, potentially leading to uncertainties in financial leadership.
Financial ForecastAdjusted EBITDA guidance for the next year falls short of market analysts' expectations.
Financial PerformanceAnalysts express concern as the company's projected EBITDA does not align with the expected market consensus.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.00%0.16%99.84%
0.16% Other Institutional Investors
99.84% Public Companies and
Individual Investors

CYL FAQ

What was Artivion’s price range in the past 12 months?
Artivion lowest stock price was €11.70 and its highest was €19.94 in the past 12 months.
    What is Artivion’s market cap?
    Currently, no data Available
    When is Artivion’s upcoming earnings report date?
    Artivion’s upcoming earnings report date is May 02, 2024 which is in 13 days.
      How were Artivion’s earnings last quarter?
      Artivion released its earnings results on Feb 15, 2024. The company reported -€0.094 earnings per share for the quarter, missing the consensus estimate of -€0.081 by -€0.013.
        Is Artivion overvalued?
        According to Wall Street analysts Artivion’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Artivion pay dividends?
          Artivion does not currently pay dividends.
          What is Artivion’s EPS estimate?
          Artivion’s EPS estimate is -€0.11.
            How many shares outstanding does Artivion have?
            Currently, no data Available
            What happened to Artivion’s price movement after its last earnings report?
            Artivion reported an EPS of -€0.094 in its last earnings report, missing expectations of -€0.081. Following the earnings report the stock price went up 3.067%.
              Which hedge fund is a major shareholder of Artivion?
              Among the largest hedge funds holding Artivion’s share is Royce & Associates LLC. It holds Artivion’s shares valued at 19M.
                ---

                Company Description

                Artivion

                CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
                ---

                CYL Company Deck

                ---

                CYL Earnings Call

                Q4 2024
                0:00 / 0:00
                ---

                CYL Stock 12 Months Forecast

                Average Price Target

                €23.52
                ▲(23.54% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","15":"€15","19":"€19","23":"€23","27":"€27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.34492,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€26.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.52225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€23.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.69958,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€20.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,15,19,23,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.58,20.100378461538458,20.62075692307692,21.14113538461538,21.661513846153845,22.181892307692305,22.70227076923077,23.22264923076923,23.74302769230769,24.26340615384615,24.783784615384615,25.304163076923075,25.82454153846154,{"y":26.34492,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.58,19.883249999999997,20.1865,20.489749999999997,20.793,21.096249999999998,21.3995,21.702749999999998,22.006,22.30925,22.6125,22.91575,23.219,{"y":23.52225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.58,19.666121538461535,19.752243076923076,19.838364615384613,19.924486153846154,20.01060769230769,20.09672923076923,20.182850769230768,20.26897230769231,20.355093846153846,20.441215384615386,20.527336923076923,20.613458461538464,{"y":20.69958,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.3,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.58,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Artivion
                Apellis Pharmaceuticals
                Avinger
                Agenus
                Arvinas Holding Company
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis